SAI MedPartners Acquires IDEA Pharma

Northlane Capital Partners Invests in SAI MedPartners

June 7, 2022

Healthcare Services

Northlane Capital Partners has made an investment in SAI MedPartners, a life-sciences consultancy providing competitive intelligence, strategy, and analytics to pharmaceutical, biotechnology, and medical device companies. The investment, made in partnership with SAI management led by Founder and CEO Erik Nordhoy, will support expansion of SAI's service offerings and global growth. SAI is headquartered in Reading, Pennsylvania and has more than 180 employees across the United States, Europe, and Asia.

SAI MedPartners Acquires PharmaForce International

March 29, 2023

Healthcare Services

SAI MedPartners, a consultancy focused on strategic insights and analytics for the pharmaceutical, biotech, and medical device industries, has acquired PharmaForce International, a Reading, Pennsylvania–based market intelligence and syndicated research firm. The acquisition adds PharmaForce's commercial benchmarking and syndicated research capabilities to SAI's competitive intelligence offerings; SAI is PE-backed by Northlane Capital Partners (which partnered with management to acquire SAI in June 2022).

SAI MedPartners Acquires Fulcrum Research Group

January 4, 2023

Healthcare Services

SAI MedPartners, a consultancy backed by Northlane Capital Partners, has acquired Fulcrum Research Group, a Waltham, MA-based primary market research firm focused on healthcare and biopharma. The add-on expands SAI's strategic insights and primary research capabilities to better serve pharmaceutical, biotechnology, and medical device clients.

SAI MedPartners Acquires The Dunn Group

December 4, 2025

Healthcare Services

SAI MedPartners, a Northlane Capital Partners-backed healthcare consultancy, has acquired The Dunn Group, a Totowa, New Jersey-based competitive intelligence firm focused on pharmaceuticals, biotechnology, and medical devices. The acquisition expands SAI's competitive intelligence capabilities and deepens its life sciences market research and analytics offerings.

Olympus Partners Acquires PAI Pharma

February 24, 2025

Pharmaceuticals

Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.

PAI Partners to Acquire SGD Pharma from China Jianyin Investment (JIC)

June 16, 2021

Packaging

PAI Partners has made a binding offer to acquire SGD Pharma, a global manufacturer of primary glass packaging for the pharmaceutical industry, from China Jianyin Investment Ltd. (JIC). The contemplated buyout, subject to employee consultations, Ministry of Finance of China approvals and antitrust clearance, aims to accelerate SGD Pharma’s growth through organic investment and external initiatives.